34687-03-1

Basic information

• Product Name: β-(NitroMethyl)benzenepropanoic Acid Methyl Ester
• Synonyms: β-(NitroMethyl)benzenepropanoic Acid Methyl Ester;methyl 4-nitro-3-phenylbutanoate
• CAS NO: 34687-03-1
• Molecular Formula: C₁₁H₁₃NO₄
• Molecular Weight: 223.22522
• Product Categories: Heterocycles, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 34687-03-1.mol
• Article Data: 18

Chemical Properties

• Melting Point: 37 °C
• Boiling Point: 346.0±35.0 °C(Predicted)
• Appearance: /
• Density: 1.182±0.06 g/cm3(Predicted)
• Solubility: Chloroform, DCM, DMSO, Ethyl Acetate
• PKA: 7.83±0.38(Predicted)
• CAS DataBase Reference: β-(NitroMethyl)benzenepropanoic Acid Methyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: β-(NitroMethyl)benzenepropanoic Acid Methyl Ester(34687-03-1)
• EPA Substance Registry System: β-(NitroMethyl)benzenepropanoic Acid Methyl Ester(34687-03-1)

Safety Data

• Hazardous Substances Data: 34687-03-1(Hazardous Substances Data)

Usage

Description

β-(NitroMethyl)benzenepropanoic Acid Methyl Ester is an organic compound that serves as a key intermediate in the synthesis of various pharmaceuticals and chemical compounds. It is characterized by its unique structure, which includes a nitro group, a methyl ester group, and a benzene ring attached to a propanoic acid chain. This versatile molecule plays a crucial role in the development of new drugs and other chemical products.

Uses

Used in Pharmaceutical Industry:
β-(NitroMethyl)benzenepropanoic Acid Methyl Ester is used as an intermediate in the synthesis of Carphedone (C184315), a GABA derivative. β-(NitroMethyl)benzenepropanoic Acid Methyl Ester has demonstrated significant immunocorrection properties during immunosuppression induced by cyclophosphamide, making it a valuable component in the development of new immunomodulatory drugs.
In the synthesis of Carphedone, β-(NitroMethyl)benzenepropanoic Acid Methyl Ester serves as a crucial building block, contributing to the formation of the final product. Its unique structure allows for further chemical modifications and reactions, enabling the creation of new compounds with potential therapeutic applications.
Furthermore, β-(NitroMethyl)benzenepropanoic Acid Methyl Ester may also be utilized in the development of other GABAergic agents, which are known to have various neurological and psychiatric applications. These agents can potentially be used in the treatment of conditions such as anxiety, epilepsy, and other neurological disorders.

Upstream product

• 75-52-5 nitromethane 
• 103-26-4 Methyl cinnamate 
• 14371-10-9 (E)-3-phenylpropenal 
• 67-56-1 methanol 
• 41441-41-2 4-nitro-3-phenyl butanoic acid 
• 1002103-54-9 4-nitro-3-phenylbutanal 
• 140-10-3 (E)-3-phenylacrylic acid 
• 2033-24-1 cycl-isopropylidene malonate 
• 100-52-7 benzaldehyde 
• 100-51-6 benzyl alcohol 
• 41441-40-1 ethyl 3-phenyl-4-nitrobutanoate 
• 103-26-4 methyl cinnamate 

Downstream Products

• 41441-41-2 4-nitro-3-phenyl butanoic acid 
• 1078-21-3 4-amino-3-phenylbutanoic acid 
• 1215863-53-8 (S)-3-cyano-3-(phenyl)-propanoic acid methyl ester 
• 1387576-65-9 (R)-methyl 3-cyano-3-phenylpropanoate 
• 62624-45-7 (S)-4-phenyl-1-tosylpyrrolidin-2-one 
• 71657-88-0 (4R)-4-phenyl-2-pyrrolidone 

Relevant articles and documents

Telescoped Continuous Flow Synthesis of Optically Active γ-Nitrobutyric Acids as Key Intermediates of Baclofen, Phenibut, and Fluorophenibut

The two-step flow asymmetric synthesis of chiral γ-nitrobutyric acids as key intermediates of the GABA analogues baclofen, phenibut, and fluorophenibut is reported on a multigram scale. The telescoped process comprises an enantioselective Michael-type add

Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design

A series of 3,4-disubstituted piperidine derivatives were obtained based on a conformational restriction strategy and a lead compound, A12, that exhibited potent in vitro and in vivo antitumor efficacies; however, obvious safety issues limited its further development. Thus, systematic exploration of the structure-activity relationship of compound A12, involving the phenyl group, hinge-linkage, and piperidine moiety, led to the discovery of the superior 3,4,6-trisubstituted piperidine derivative E22. E22 showed increased potency in Akt1 and cancer cell inhibition, remarkably reduced human ether-a-go-go-related gene blockage, and significantly improved safety profiles. Compound E22 also exhibited good kinase selectivity, had a good pharmacokinetic profile, and displayed very potent in vivo antitumor efficacy, with over 90% tumor growth inhibition in the SKOV3 xenograft model. Further mechanistic studies were conducted to demonstrate that compound E22 could significantly inhibit the phosphorylation of proteins downstream of Akt kinase in cells and tumor tissue from the xenograft model.

A process for preparing 3 - phenyl - 4 - aminobutyric acid hydrochloride process (by machine translation)

The present invention provides a process for preparing 3 - phenyl - 4 - aminobutyric acid hydrochloride of the process, the use of cinnamic acid methyl ester and nitromethane as the reaction substrate, nitromethane can be used as the reaction substrate bu